{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:46:16Z","timestamp":1791582376791,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"DOI":"10.3389\/fgene.2019.00461","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T13:24:07Z","timestamp":1558013047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson\u2019s Disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Sara","family":"Reden\u0161ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Jenko Bizjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Tro\u0161t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Dol\u017ean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1517\/17425255.2013.789018","article-title":"Anti-Parkinson\u2019s disease drugs and pharmacogenetic considerations.","volume":"9","author":"Agundez","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3109\/10409238.2010.516740","article-title":"Survivin: a target from brain cancer to neurodegenerative disease.","volume":"45","author":"Baratchi","year":"2010","journal-title":"Crit. Rev. Biochem. Mol. Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/jnc.13125","article-title":"Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.","volume":"134","author":"Bhide","year":"2015","journal-title":"J. Neurochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: filling the bench-to-bedside gap.","volume":"9","author":"Calabresi","year":"2010","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa.","volume":"137","author":"Cilia","year":"2014","journal-title":"Brain"},{"key":"B6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3892\/br.2014.296","article-title":"Association of NQO1 and TNF polymorphisms with Parkinson\u2019s disease: a meta-analysis of 15 genetic association studies.","volume":"2","author":"Dai","year":"2014","journal-title":"Biomed. Rep."},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-018-0931-2","article-title":"Recommendations for the design of small population clinical trials.","volume":"13","author":"Day","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neulet.2016.02.011","article-title":"Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson\u2019s disease and its progression: disease and staging biomarkers and new drug targets.","volume":"617","author":"de Farias","year":"2016","journal-title":"Neurosci. Lett."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-018-0069-x","article-title":"Risk factors of levodopa-induced dyskinesia in Parkinson\u2019s disease: results from the PPMI cohort.","volume":"4","author":"Eusebi","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/jnnp.2008.154294","article-title":"BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson\u2019s disease.","volume":"80","author":"Foltynie","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/1544-6115.1815","article-title":"Time dependent ROC curves for the estimation of true prognostic capacity of microarray data.","volume":"11","author":"Foucher","year":"2012","journal-title":"Stat. Appl. Genet. Mol. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/bimj.200900028","article-title":"L1 penalized estimation in the Cox proportional hazards model.","volume":"52","author":"Goeman","year":"2010","journal-title":"Biom. J."},{"key":"B13","author":"Goetz","year":"2008","journal-title":"MDS-UPDRS."},{"key":"B14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/tpj.2016.36","article-title":"Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.","volume":"17","author":"Jenko","year":"2017","journal-title":"Pharmacogenom. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/pgs.15.147","article-title":"Survivin polymorphism is associated with disease activity in rheumatoid arthritis patients.","volume":"17","author":"Jenko","year":"2016","journal-title":"Pharmacogenomics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease.","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.envres.2016.09.006","article-title":"Gene-environment interactions linking air pollution and inflammation in Parkinson\u2019s disease.","volume":"151","author":"Lee","year":"2016","journal-title":"Environ. Res."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162866","article-title":"A european spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics.","volume":"11","author":"Mizzi","year":"2016","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jclinepi.2004.01.020","article-title":"Penalized maximum likelihood estimation to directly adjust diagnostic and prognostic prediction models for overoptimism: a clinical example.","volume":"57","author":"Moons","year":"2004","journal-title":"J. Clin. Epidemiol."},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease.","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-017-8473-7","article-title":"Genetics and treatment response in Parkinson\u2019s disease: an update on pharmacogenetic studies.","volume":"20","author":"Politi","year":"2018","journal-title":"Neuromol. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00401-008-0438-3","article-title":"Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson\u2019s disease and dementia with Lewy bodies.","volume":"117","author":"Power","year":"2009","journal-title":"Acta Neuropathol."},{"key":"B23","year":"2018","journal-title":"R: A Language and Environment for Statistical Computing."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00008","article-title":"Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson\u2019s disease.","volume":"10","author":"Reden\u0161ek","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00020","article-title":"Genetic determinants of Parkinson\u2019s disease: can they help to stratify the patients based on the underlying molecular defect?.","volume":"9","author":"Reden\u0161ek","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"B26","article-title":"Effects of genetic variability in dopaminergic pathway on treatment response in Parkinson\u2019s disease","author":"Reden\u0161ek","year":"2018","journal-title":"Parkinson\u2019s Disease"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/jnr.22045","article-title":"The effect of a promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to Parkinson\u2019s disease.","volume":"87","author":"Rife","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.neulet.2011.11.032","article-title":"Gender differences in the IL6 -174G > C and ESR2 1730G > a polymorphisms and the risk of Parkinson\u2019s disease.","volume":"506","author":"San Luciano","year":"2012","journal-title":"Neurosci. Lett."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109042","article-title":"Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson\u2019s disease.","volume":"9","author":"Santiago","year":"2014","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2017.06.004","article-title":"Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson\u2019s disease.","volume":"74","author":"Santos-Lobato","year":"2017","journal-title":"Nitric Oxide"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-017-0032-2","article-title":"Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson\u2019s disease.","volume":"3","author":"Sarkar","year":"2017","journal-title":"NPJ Parkinsons Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.parkreldis.2010.06.003","article-title":"Classifying risk factors for dyskinesia in Parkinson\u2019s disease.","volume":"16","author":"Sharma","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12031-014-0482-5","article-title":"Genetic variability testing of neurodevelopmental genes in schizophrenic patients.","volume":"56","author":"Terzic","year":"2015","journal-title":"J. Mol. Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.brainres.2017.06.012","article-title":"Neuregulin-1 protects mouse cerebellum against oxidative stress and neuroinflammation.","volume":"1","author":"Xu","year":"2017","journal-title":"Brain Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"W600","DOI":"10.1093\/nar\/gkp290","article-title":"SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies.","volume":"37","author":"Xu","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00259-017-3844-8","article-title":"Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson\u2019s disease.","volume":"45","author":"Yoo","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00441-018-2813-2","article-title":"Molecular basis of dopamine replacement therapy and its side effects in Parkinson\u2019s disease.","volume":"373","author":"You","year":"2018","journal-title":"Cell Tissue Res."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fgene.2019.00461\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T13:24:11Z","timestamp":1558013051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fgene.2019.00461\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":37,"alternative-id":["10.3389\/fgene.2019.00461"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2019.00461","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,16]]},"article-number":"461"}}